- Home
- SAFT vs GYRE Comparison
SAFT vs GYRE Comparison
Compare SAFT & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SAFT
- GYRE
- Stock Information
- Founded
- SAFT 1979
- GYRE 2002
- Country
- SAFT United States
- GYRE United States
- Employees
- SAFT N/A
- GYRE N/A
- Industry
- SAFT Property-Casualty Insurers
- GYRE Biotechnology: Pharmaceutical Preparations
- Sector
- SAFT Finance
- GYRE Health Care
- Exchange
- SAFT Nasdaq
- GYRE Nasdaq
- Market Cap
- SAFT 1.1B
- GYRE 990.4M
- IPO Year
- SAFT N/A
- GYRE N/A
- Fundamental
- Price
- SAFT $76.86
- GYRE $8.88
- Analyst Decision
- SAFT
- GYRE
- Analyst Count
- SAFT 0
- GYRE 0
- Target Price
- SAFT N/A
- GYRE N/A
- AVG Volume (30 Days)
- SAFT 75.7K
- GYRE 209.4K
- Earning Date
- SAFT 05-07-2025
- GYRE 05-19-2025
- Dividend Yield
- SAFT 4.69%
- GYRE N/A
- EPS Growth
- SAFT 273.44
- GYRE N/A
- EPS
- SAFT 4.78
- GYRE 0.05
- Revenue
- SAFT $1,120,017,000.00
- GYRE $105,757,000.00
- Revenue This Year
- SAFT N/A
- GYRE $22.01
- Revenue Next Year
- SAFT N/A
- GYRE $88.14
- P/E Ratio
- SAFT $16.08
- GYRE $184.70
- Revenue Growth
- SAFT 20.31
- GYRE N/A
- 52 Week Low
- SAFT $70.71
- GYRE $6.11
- 52 Week High
- SAFT $90.00
- GYRE $19.00
- Technical
- Relative Strength Index (RSI)
- SAFT 48.46
- GYRE 51.54
- Support Level
- SAFT $73.77
- GYRE $7.03
- Resistance Level
- SAFT $80.02
- GYRE $8.44
- Average True Range (ATR)
- SAFT 2.71
- GYRE 1.12
- MACD
- SAFT -0.01
- GYRE 0.23
- Stochastic Oscillator
- SAFT 59.82
- GYRE 92.33
About SAFT Safety Insurance Group Inc.
Safety Insurance Group Inc is a provider of private passenger automobile insurance in Massachusetts. The company also offers property and casualty insurance products, including commercial automobiles, homeowners, dwelling fire, umbrella, and business owner policies. It operates in the business segment of Property and casualty insurance operations.
About GYRE Gyre Therapeutics Inc.
Gyre Therapeutics Inc is a biopharmaceutical company headquartered in San Diego, CA, that is primarily focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis), formerly known as Nonalcoholic Steatohepatitis (NASH)) in the United States. In the United States, Hydronidone is currently being evaluated for the treatment of liver fibrosis across a broad spectrum of chronic liver diseases under an active Investigational New Drug (IND) application. Gyre is also advancing a diverse pipeline in China through a controlling interest in the Beijing Continent, including pirfenidone, F573, F528, and F230.